Genomic Vision Announces the Approval by its General Meeting of all the Resolutions Recommended by the Management Board
10 Août 2020 - 5:46PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in in-vitro diagnostic (IVD) tests for the early
detection of cancers and genetic diseases, and in the development
of applications for life sciences research (LSR), informs its
shareholders that Combined Shareholders’ Meeting held today in
camera, was able to deliberate as the required quorum was
reached.
The shareholders of Genomic Vision voted in favour of all the
resolutions presented in line with the recommendations of the
Management Board.
In particular, the meeting approved the setting up of a
financing line with Winance, the Company's financial partner,
through a reserved issuance of convertible notes with warrants
(OCABSA) for a maximum amount of €12 million in order to secure the
Company's potential needs in terms of investment and financing of
growth over the next 2 or 3 years.
Genomic Vision would like to thank all its shareholders for
their commitment and support.
The minutes of the combined shareholders' meeting of August 10,
2020 will be available within the legal deadlines on the Company's
website, under the heading Investors/General Meetings.
***
ABOUT GENOMIC VISION GENOMIC VISION is a biotechnology
company developing products and services dedicated to the analysis
(structural and functional) of genome modifications as well as to
the quality and safety control of these modifications, in
particular in genome editing technologies and biomanufacturing
processes. Genomic Vision proprietary tools, based on DNA combing
technology and artificial intelligence, provide robust quantitative
measurements needed to high confidence characterization of DNA
alteration in the genome. These tools are mainly used for
monitoring DNA replication in cancerous cell, for early cancer
detection and the diagnosis of genetic diseases. Based near Paris,
in Bagneux, the Company has approximately 30 employees. GENOMIC
VISION is a public listed company listed in compartment C of
Euronext’s regulated market in Paris (Euronext: GV – ISIN:
FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT This press release contains
implicitly or explicitly certain forward-looking statements
concerning Genomic Vision and its business. Such forward-looking
statements are based on assumptions that Genomic Vision considers
to be reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
“Risk Factors” section of the reference document dated March 29,
2019 filed with the AMF under reference number R19-004, available
on the web site of Genomic Vision (www.genomicvision.com) and to
the development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200810005536/en/
Genomic Vision Dominique Rémy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024